Editorial
Copyright ©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 80-93
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Table 3 Tyrosine kinase inhibitors of the platelet derived growth factor receptor tyrosine kinase family
InhibitorTyrosine kinase targetNeoplasm(s) targetedClinical status
Leflunomide (SU101)PDGFRβ, EGFR, FGFRProstate cancerPhase II/III
Lestaurtinib (CEP-701)Flt3, Trk, VEGFR2Leukemia, pancreatic, AMLPhase II
Tandutinib (MLN518)Flt3, PDGFRβ, KitAMLPhase I/II
SU14813VEGFR2, PDGFRβ, Flt3Adv malignanciesPhase I, suspended
XL999FGFR, VEGFR1/2/3, PDGFRβ, Flt3CancerPhase II, suspended
VX-322Flt3, KitAMLPreclinical
SU5614Flt3AML, solid tumorsPreclinical, suspended
GTP-14564Flt3AMLPreclinical
KI23819Flt3AMLPreclinical
Gö6976Flt3, JAK2AMLPreclinical
AG1296PDGFRβ, Kit, Flt3AMLPreclinical
PKC412Kit, PDGFRβ, PKC, Flt3, VEGFR2Solid tumorsPhase II
OSI 817Kit, VEGFRSolid tumorsPreclinical
CP-868596PDGFRβAdv solid tumorsPhase I
NSCLCPhase II